Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Targeting PRDX1-G6PD Interaction Promotes a Metabolic Vulnerability and Redox Imbalance in Triple-Negative Breast Cancer.

Created on 19 Oct 2026

Authors

Hongru Tao, Ningyun Liu, Ziang Hu, Yixuan Xu, Heng Xu, Yuanyuan Zhang, Cheng Luo

Published in

Free radical biology & medicine. Oct 18, 2026. Epub Oct 18, 2026.

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited targeted options, and its progression is strongly driven by metabolic reprogramming and redox homeostasis. Here, we found that peroxiredoxin-1 (PRDX1) promotes TNBC progression by directly interacting with glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the pentose phosphate pathway (PPP). Mechanistically, PRDX1 depletion reduced the formation of active G6PD dimers without affecting its expression, thereby impairing PPP metabolism and ultimately suppressing TNBC growth. Furthermore, we identified the natural product Oridonin as a small-molecule disruptor that blocked the PRDX1-G6PD interaction. Pharmacological intervention with Oridonin impaired G6PD dimerization, disrupted intracellular redox homeostasis and suppressed TNBC tumor growth in vivo. Taken together, our study unveils the critical role of the PRDX1-G6PD protein complex in PPP-dependent metabolic reprogramming and redox homeostasis in TNBC, and identifies this axis as a targetable vulnerability against TNBC.

PMID:
42893758
Bibliographic data and abstract were imported from PubMed on 19 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 27
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement